Mallinckrodt (MNK) wins IPR decisions on INOMax blood-vessel drug - Bloomberg
- Wall Street flat as banks gain, utilities drag
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mallinckrodt (NYSE: MNK) wins IPR decisions on INOMax blood-vessel drug, according to Bloomberg.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alaska Air Group (ALK) Cleared by DOJ to Acquire Virgin America (VA)
- Financial Select Sector SPDR ETF (XLF) calls active on 4 calls to 1 put
- Chipotle (CMG) volatility comes in after company says sales haven't recovered as much as previously expected